Trial reportEuropean journal of clinical pharmacology2003
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Trial report in European journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).The Cochrane database of systematic reviews · 2012Pooled it
- Guideline
- Pandemic flu. Clinical management of patients with an influenza-like illness during an influenza pandemic.The Journal of infection · 2006Guideline
- Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.European journal of drug metabolism and pharmacokinetics · 2018Trial
- Oseltamivir dosing in premature infants.The Journal of infectious diseases · 2012Trial
- Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.Antimicrobial agents and chemotherapy · 2012Trial
- Pharmacologic background and clinical issue of anti-influenza drugs.Fukushima journal of medical science · 2025Review
- A comparison of different methods for the first-in-pediatric dose selection.Journal of clinical and translational research · 2022Article
- Ontogeny of Drug-Metabolizing Enzymes.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations.The AAPS journal · 2020Article
- Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.Clinical pharmacology and therapeutics · 2020Article
- Clinical Pharmacology Studies in Critically Ill Children.Pharmaceutical research · 2017Review
- Pharmacokinetics of oseltamivir in infants under the age of 1 year.Clinical and translational medicine · 2016Article
- Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.PLoS computational biology · 2014Article
- Bench to bed evidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and chinese medicine.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.Antimicrobial agents and chemotherapy · 2013Article
- The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.British journal of clinical pharmacology · 2012Review
- Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation.Biochemical pharmacology · 2012Article
- Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.Journal of perinatology : official journal of the California Perinatal Association · 2011Article
- Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.Paediatric drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prodrug oseltamivir has been shown to be efficacious and safe for the treatment of influenza for patients 1 year of age or older; however, pharmacokinetic information was lacking for children below 5 years of age. This study was conducted to assess the metabolic and excretory capacity of oseltamivir and its active carboxylate metabolite in young children.
methodsTwelve healthy children aged 1-5 years received a single oral suspension dose of oseltamivir (45 mg for 3-5 years, 30 mg for 1-2 years). Plasma and urine concentrations of oseltamivir and the carboxylate were determined by means of liquid chromatography/tandem mass spectrometry.
resultsMean peak plasma concentration and area under the plasma concentration-time curve values normalized to milligram per kilogram oseltamivir dose in the 1- to 2-year group are lower than those in the 3- to 5-year group. Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).
conclusionThe results demonstrate that infants as young as 1 year old can metabolize and excrete oseltamivir efficiently. The data derived from this study provide the starting dose of oseltamivir for further investigation in an efficacy study among influenza-infected infants less than 1 year of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.